Meet us at the London Valves Conference in November 2024
Venus Medtech is committed to structural heart innovation. Our exceptional heart valve solutions target all four heart valves.
Be sure to join our symposium at London Valves to better understand the mechanisms of action of the state-of-art Cardiovalve Replacement System for Tricuspid and Mitral Valve diseases and its current results.
More information will follow. Stay Tuned.
Venus Medtech is committed to structural heart innovation. Our exceptional heart valve solutions target all four heart valves.
Be sure to join our symposium at London Valves to better understand the mechanisms of action of the state-of-art Cardiovalve Replacement System for Tricuspid and Mitral Valve diseases and its current results.
MAGNIFY INNOVATION
WITNESS QUALITY:
Attend the session to learn the latest about structural heart intervention
WITNESS QUALITY:
Attend the session to learn the latest about structural heart intervention
You are welcome to listen to top investigators who will discuss the latest results and future plans for the state-of-art Cardiovalve Replacement System for treating Tricuspid and Mitral Valve diseases.
Join our symposium: November 24th, 17:20-18:20, Room 4
Innovation never stops: Cardiovalve in action!
Join this session if you want:
- To understand the anatomical and imaging challenges. associated with transcatheter tricuspid valve replacement
- To gain insights into the latest advances in this rapidly developing clinical field.
- To get an update on current developments in the Cardiovalve tricuspid clinical program.
Anchorperson : Didier Tchetche
Spokesperson: Georg Nickenig
Discussants: Federico De Marco, Rodrigo Estevez Loureiro, Xavier Freixa, Sergio Berti
17:20
Welcome and session objectives
Didier Tchetche
17:23
Cardiovalve tricuspid replacement system: Latest clinical updates
Prof. Georg Nickenig
17:34
A happy wedding: Live- in- a-box
Xavier Freixa
17:45
Transcatheter tricuspid valve replacement in rheumatic valve disease
Federico De Marco
17:56
Hot news in imaging: Transcatheter tricuspid valve replacement using intracardiac echocardiographic guidance
Sergio Berti
18:07
Rapid learning curve: A single-site experience
Rodrigo Estevez Loureiro
18:18
Session evaluation and key learnings
Georg Nickenig
Learn more about TARGET
Multicenter Study
Learn more about the TARGET study below.
Multi-center Study
The TARGET Study
Evaluate the safety and performance of the Cardiovalve TR System with its associated procedure in reducing tricuspid regurgitation, signs of TR, and symptoms from TR.
150 participants
A total of 150 subjects will be enrolled. Up to a 5 year follow up.
Up to 50 Medical Center
Centers will be located in North America and Asia
Endpoints
Symptomatic subjects (NYHA Class ≥ II-IVa) with at least severe tricuspid regurgitation (≥3+ in a 5-tier grading) requiring valve replacement or repair who are at high risk for open chest surgery according to the Heart Team decision and approved by the Subject Screening Committee.
Innovation Never Stops!